Human cell experts from Germany’s CO.DON AG are again cutting the edge: they have launched human cells production on an industrial scale. The demanding quality standards required of the manufacturing conditions for human cell transplants led to the development of Integrated Isolator Technology (IIT) alongside industrial partners, which went into operation at CO.DON´s Teltow site in 1999. [Read more…]
What is CAR-T Cell Therapy? A New Way to Treat Cancer
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients across the globe. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.
For those who are facing cancer, it is important to answer the question “What is CAR-T?” This guide will answer the most common questions about CAR-T cell therapy for readers who want to understand this novel technology platform for treating cancer. [Read more…]
Legend Biotech’s CARVYKTI™ Becomes Latest CAR-T Therapy Approved by U.S. FDA
-
CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
-
CARVYKTI™ marks the first product approved by a health authority for Legend Biotech
-
Approval is primarily based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with refractory or relapsed multiple myeloma after four or more prior lines of therapy including proteasome inhibitor, immunomodulatory agent and anti-CD38 monoclonal antibody1
FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers
CYNK-101 is an investigational genetically modified NK cell therapy designed to synergize with antibody therapeutics for difficult to treat cancers of high unmet medical need
Phase 1/2a clinical trial will evaluate the safety and preliminary efficacy of CYNK-101 in combination with standard chemotherapy, trastuzumab, and pembrolizumab
5th designation received by Celularity within 12 months from the US FDA
GIOSTAR Chicago Explores Holistic Healing with Chopra Global Chief Medical Officer
Company continues analysis of innovative approaches to healthcare with pioneer in the space
CHICAGO, Feb. 22, 2022 — GIOSTAR Chicago – a leader in regenerative technologies – recently conducted a discussion on holistic healing with Dr. Sheila Patel. The conversation was led by Shelly Sood, GIOSTAR Chicago Founding Partner. Dr. Patel is a board-certified family physician and Chief Medical Officer (CMO) of Chopra Global – “a modern healthcare company positioned at the intersection of science and spirituality,” founded by renowned healthcare expert Dr. Deepak Chopra. The full interview is available on the GIOSTAR Chicago Website, with an accompanying transcript. [Read more…]
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 47
- Next Page »